Innovative AI-driven proteogenomic analysis company applies single cell analysis expertise to developing treatments for COVID-19
The current global health crisis demands teams to put their best tools together and act quickly. Without an effective treatment for COVID-19, new therapies targeting the SARS-CoV-2 virus are in urgent need.
Single cell sequencing technology is one of the latest scientific breakthroughs. How can this powerful platform be used to combat today’s pandemic?
Proteona has recently announced that it is leading a global alliance to develop a neutralizing antibody against coronaviruses, including SARS-CoV-2, the virus causing COVID-19. The key technology used are Proteona’s single cell analysis platform and AI data analytics.
At 10am GMT+8 April 4th, listen to Proteona CEO Dr Andreas Schmidt explain the science behind in a live interview.
Tune in at Weekend Mornings with Glenn van Zutphen, Money FM 89.3 on your radio or online!
For media queries, please contact:
Dr Andreas Schmidt
Proteona Antibody Protection GmbH
About Proteona Antibody Protection GmbH
Proteona Antibody Protection GmbH is a biomedical company operating at the forefront of the fight against COVID-19 using single cell sequencing technology to discover neutralizing antibodies. Proteona’s vision is to accelerate treatment development for the most vulnerable, immunocompromised patients. Its parent company, Proteona, is already active in Singapore and Germany, where it provides single-cell multi-omics data for researchers, clinicians and pharma companies for drug discovery and for treatment optimization for blood cancer patients.